RESUMO
BACKGROUND: Patients with epithelial ovarian carcinoma upstaged from Stage I/II to Stage IIIC based on lymph node involvement are known to have poor prognoses. The authors investigated whether systematic aortic and pelvic lymphadenectomy would affect the prognoses of these patients. METHODS: During the period 1987-1996, 103 patients in Stage I-III underwent optimal cytoreductive surgery with systematic aortic and pelvic lymphadenectomy at initial surgery. All patients except for those in Stage IA received adjuvant cisplatin-based chemotherapy after surgery. Of 67 patients with intraperitoneal tumors limited to the pelvis, 14 were upstaged to Stage III based on lymph node positivity (Group A). The authors compared the survival of Group A patients with that of 53 patients who had intraperitoneal tumors limited to the pelvis and negative lymph nodes (Group B), and also with that of 36 patients who had intraperitoneal tumors beyond the pelvis irrespective of lymph node status (Group C). RESULTS: The 5-year survival of Group A patients in Stage III based only on lymph node positivity had fairly good survival, although it was not significantly different from that of Group B patients in Stage I/II (84% vs. 96%, P=0.107). Group A had much better 5-year survival than Group C patients who were considered to be Stage III because they had intraperitoneal tumors beyond the pelvis (84% vs. 26%, P=0.042). CONCLUSIONS: Relatively good survival was observed for patients with intraperitoneal tumors limited to the pelvis and lymph node involvement who underwent systematic aortic and pelvic lymphadenectomy.
Assuntos
Carcinoma/patologia , Excisão de Linfonodo , Linfonodos/patologia , Neoplasias Ovarianas/patologia , Adulto , Idoso , Antibióticos Antineoplásicos/administração & dosagem , Antimetabólitos Antineoplásicos/administração & dosagem , Antineoplásicos/administração & dosagem , Antineoplásicos Alquilantes/administração & dosagem , Antineoplásicos Fitogênicos/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Aorta , Carcinoma/cirurgia , Quimioterapia Adjuvante , Cisplatino/administração & dosagem , Ciclofosfamida/administração & dosagem , Doxorrubicina/administração & dosagem , Etoposídeo/administração & dosagem , Feminino , Fluoruracila/administração & dosagem , Seguimentos , Humanos , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Neoplasias Ovarianas/cirurgia , Pelve , Neoplasias Peritoneais/patologia , Prognóstico , Taxa de SobrevidaRESUMO
I. Interactions of angiotensin II and norepinephrine in the rat hypothalamus and other brainstem were studied by intraventricular perfusion or/and intravenous administration. (1) Intravenous administration of angiotensin reduced the hypothalamus norepinephrine content. (2) Intraventricularly perfused angiotensin reduced the hypothalamus norepinephrine but did not alter that in other parts of brainstem. Hypothalamus norepinephrine was reduced more by intravenous administration of angiotensin than by intraventricularly perfused angiotensin. II. The involvements of adrenergic mechanism in the central pressor effect of angiotensin II were studied through observation of blood pressure changes following injection of angiotensin II, phentolamine and propranolol into the rabbit lateral ventricle of rabbit brain.(1) Intraventricular administration of phentolamine suppressed the central mediated pressor respons of angiotensin. (2) Simultaneous intraventricular administration of propranolol enhanced the angiotensin pressor effect in anesthetized rabbits.
Assuntos
Angiotensina II/farmacologia , Pressão Sanguínea/efeitos dos fármacos , Receptores Adrenérgicos , Angiotensina II/administração & dosagem , Animais , Tronco Encefálico/análise , Ventrículos Cerebrais , Hipotálamo/análise , Injeções Intravenosas , Masculino , Norepinefrina/análise , Perfusão , Fentolamina/farmacologia , Propranolol/farmacologia , Coelhos , RatosRESUMO
1. Intravenous administration of angiotensin II reduced the adrenaline content, increased the catechol-O-methyltransferase activity, and decreased the monoamine oxidase activity of rat hypothalamus. 2. Intraventricularly administrated angiotensin II reduced the noradreanline content to a smaller extent. 3. The change produced by intravenous administration of angiotensin might be indirectly caused by a response to angiotensin.